EXAS250117P92500
- 29.50
- 0.000.00%
Exact Sciences Newsroom
Evercore Maintains Exact Sciences(EXAS.US) With Buy Rating, Cuts Target Price to $70
Exact Sciences Price Target Raised to $70 From $60 at Evercore ISI
Exact Sciences to Participate in J.P. Morgan Healthcare Conference
(EXAS) - Analyzing Exact Sciences's Short Interest
Would Exact Sciences (NASDAQ:EXAS) Be Better Off With Less Debt?
Analysts Are Bullish on These Healthcare Stocks: Exact Sciences (EXAS), Neurocrine (NBIX)
Exact Sciences Is Maintained at Buy by B of A Securities
Exact Sciences Analyst Ratings
BofA Securities Maintains Exact Sciences(EXAS.US) With Buy Rating, Cuts Target Price to $72
10 BofA U.S. Options Overwriting Ideas
Express News | Exact Sciences Corp : Leerink Partners Raises Target Price to $95 From $70
TD Cowen Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $86
Exact Sciences (EXAS) Gets a Buy From TD Cowen
AAPA Awarded Grant From Exact Sciences to Improve Colorectal Cancer Screening Rates
Exact Sciences Corporation's (NASDAQ:EXAS) Shares Lagging The Industry But So Is The Business
Exact Sciences Corporation (EXAS) Annual Evercore ISI HealthCONx Healthcare Conference (Transcript)
Exact Sciences Corporation (EXAS) Citi's 2024 Global Healthcare Conference (Transcript)
Big Pharma Pushes To Revise Biden-era Medicare Drug Price Negotiation Law Under Trump
Exact Sciences and Lil Jon Partner on "Get Low #2" Campaign to Encourage Colon Cancer Screening
Trending Stocks This Week as Holiday Season Begins With Thanksgiving Break